Skip to content
Study details
Enrolling now

A Phase 1 Trial of TORL-4-500 in People with Advanced Cancer

TORL Biotherapeutics, LLC
NCT IDNCT06005740ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

70

Study length

about 2.9 years

Ages

18+

Locations

8 sites in AZ, CA, FL +2

What this study is about

This trial is testing the safety and how well TORL-4-500 works in people who have advanced cancer. The goal is to see if it's safe for adults, and to learn more about how it affects the body.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take TORL-4-500

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Incidence and severity of adverse events and serious adverse events, Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D)

Secondary: 1 Year Overall Survival (1YOS), 2 Year Overall Survival (2YOS), Clearance (CL) of TORL-4-500, Duration of Response (DOR), Maximum Serum Concentration of TORL-4-500 (Cmax), Maximum Serum Concentration of TORL-4-500 at Steady State (Cmax,ss), Objective Response Rate (ORR), Progression Free Survival (PFS)

Body systems

Oncology